litlas
Log inCreate account

Lecia V. Sequist

Active 2005–2025

211
Papers
73,311
Citations
119
h-index
206
i10-index

Citations

Citations per year for Lecia V. Sequist1945: 1 citations1985: 1 citations1987: 1 citations1989: 1 citations1999: 1 citations2000: 1 citations2001: 2 citations2003: 1 citations2004: 6 citations2005: 2 citations2006: 7 citations2007: 43 citations2008: 102 citations2009: 176 citations2010: 235 citations2011: 479 citations2012: 623 citations2013: 900 citations2014: 883 citations2015: 1,109 citations2016: 1,238 citations2017: 1,297 citations2018: 1,293 citations2019: 3,411 citations2020: 3,409 citations2021: 3,235 citations2022: 2,480 citations2023: 1,888 citations2024: 2,568 citations2025: 1,374 citations2026: 62 citations1946–1984: no citations, so these years are not shown1986: no citations, so this year is not shown1988: no citations, so this year is not shown1990–1998: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,907 citing papers, 25.6% of this breakdownChina: 4,730 citing papers, 17.5% of this breakdownItaly: 1,282 citing papers, 4.8% of this breakdownUnited Kingdom: 1,219 citing papers, 4.5% of this breakdownJapan: 1,182 citing papers, 4.4% of this breakdownGermany: 1,104 citing papers, 4.1% of this breakdownFrance: 963 citing papers, 3.6% of this breakdownSpain: 841 citing papers, 3.1% of this breakdownSouth Korea: 819 citing papers, 3% of this breakdownCanada: 713 citing papers, 2.6% of this breakdownNetherlands: 615 citing papers, 2.3% of this breakdownAustralia: 611 citing papers, 2.3% of this breakdown
0%25.6%Other 22.2%

Institutions

Fields

  • Medicine63%
  • Biochemistry, Genetics and Molecular Biology28.3%
  • Engineering3.2%
  • Immunology and Microbiology1.7%
  • Computer Science1%
  • Chemistry0.7%
  • Other2.1%

Topics

  • Lung Cancer Treatments and Mutations12.1%
  • Cancer Genomics and Diagnostics6.9%
  • Lung Cancer Research Studies5.5%
  • Cancer Immunotherapy and Biomarkers5.3%
  • Cancer Cells and Metastasis4.8%
  • Lung Cancer Diagnosis and Treatment4.1%
  • Other61.3%

Coauthors

All papers

Open in search
  1. Lung cancer

    Authors: Alesha Thai, Benjamin Solomon, Lecia V. Sequist, Justin F. Gainor, Rebecca S. Heist - The Lancet 2021 cited by 2,524

  2. Integrating genomic features for non-invasive early lung cancer detection

    Authors: Jacob J. Chabon, Emily G. Hamilton, David M. Kurtz, Mohammad Shahrokh Esfahani, Everett J. Moding, Henning Stehr, Joseph G. Schroers‐Martin, Barzin Y. Nabet, Binbin Chen, Aadel A. Chaudhuri, Chih Long Liu, Angela BY Hui, Michael C. Jin, Tej D. Azad, Diego Almanza, Young-Jun Jeon, Monica Nesselbush, Lyron Co Ting Keh, Rene F. Bonilla, Christopher H. Yoo, Ryan B. Ko, Emily Chen, David J. Merriott, Pierre P. Massion, Aaron S. Mansfield, Jin Jen, Hong Ren, Steven H. Lin, Christina L. Costantino, Risa Burr, Robert Tibshirani, Sanjiv S. Gambhir, Gerald J. Berry, Kristin C. Jensen, Robert B. West, Joel W. Neal, Heather A. Wakelee, Billy W. Loo, Christian A. Kunder, Ann N. Leung, Natalie S. Lui, Mark F. Berry, Joseph B. Shrager, Viswam S. Nair, Daniel A. Haber, Lecia V. Sequist, Ash A. Alizadeh, Maximilian Diehn - Nature 2020 cited by 703

  3. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

    Authors: Alissa J. Cooper, Lecia V. Sequist, Jessica J. Lin - Nature Reviews Clinical Oncology 2022 cited by 483

  4. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Authors: Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Subba R. Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer S. Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman - Science Translational Medicine 2011 cited by 3,556

  5. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    Authors: Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési, Trever G. Bivona, Maximilian Diehn, Caroline Dive, Rafał Dziadziuszko, Natasha B. Leighl, Umberto Malapelle, Tony Mok, Nir Peled, Luis E. Raez, Lecia V. Sequist, Lynette M. Sholl, Charles Swanton, Chris Abbosh, Daniel S.W. Tan, Heather A. Wakelee, Ignacio I. Wistuba, Rebecca A. Bunn, Janet Freeman‐Daily, Murry W. Wynes, Chandra P. Belani, Tetsuya Mitsudomi, David R. Gandara - Journal of Thoracic Oncology 2021 cited by 645

  6. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    Authors: Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa Wells, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran - Science 2013 cited by 2,496

  7. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Authors: Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler - Journal of Clinical Oncology 2013 cited by 3,198

  8. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Authors: Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, María Gomez‐Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo-Eun Carrie Bhang, Viveksagar Krishnamurthy Radhakrishna, Giulia Siravegna, Haichuan Hu, Sana Raoof, Elizabeth L. Lockerman, Anuj Kalsy, Dana Lee, Celina L Keating, David A. Ruddy, Leah J. Damon, Adam Crystal, Carlotta Costa, Zofia Piotrowska, Alberto Bardelli, A. John Iafrate, Ruslan I. Sadreyev, Frank Stegmeier, Gad Getz, Lecia V. Sequist, Anthony C. Faber, Jeffrey A. Engelman - Nature Medicine 2016 cited by 999

  9. Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

    Authors: Peter G. Mikhael, Jeremy Wohlwend, Adam Yala, Ludvig Karstens, Justin Xiang, A. Takigami, Patrick Bourgouin, PuiYee Chan, Sofiane Mrah, Wael Amayri, Yu‐Hsiang Juan, Cheng‐Ta Yang, Yung‐Liang Wan, Gigin Lin, Lecia V. Sequist, Florian J. Fintelmann, Regina Barzilay - Journal of Clinical Oncology 2023 cited by 250

  10. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

    Authors: Haichuan Hu, Zofia Piotrowska, Patricia J. Hare, Huidong Chen, Hillary E. Mulvey, Aislinn Mayfield, Sundus Noeen, Krystina E. Kattermann, Max Greenberg, August Williams, Amanda K. Riley, Jarad Wilson, Yingqing Mao, Ruo‐Pan Huang, Mandeep K. Banwait, Jeffrey Ho, Giovanna Stein Crowther, Lida P. Hariri, Rebecca S. Heist, David P. Kodack, Luca Pinello, Alice T. Shaw, Mari Mino–Kenudson, Aaron N. Hata, Lecia V. Sequist, Cyril H. Benes, Matthew J. Niederst, Jeffrey A. Engelman - Cancer Cell 2021 cited by 261

  11. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Authors: Matthew G. Oser, Matthew J. Niederst, Lecia V. Sequist, Jeffrey A. Engelman - The Lancet Oncology 2015 cited by 949

  12. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

    Authors: Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba R. Digumarthy, Teresa Morán, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino–Kenudson - Clinical Cancer Research 2016 cited by 1,241

  13. Isolation of rare circulating tumour cells in cancer patients by microchip technology

    Authors: Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran, Daphne W. Bell, Daniel Irimia, Lindsey Ulkus, Matthew R. Smith, Eunice L. Kwak, Subba R. Digumarthy, Alona Muzikansky, Paula D. Ryan, Ulysses J. Balis, Ronald G. Tompkins, Daniel A. Haber, Mehmet Toner - Nature 2007 cited by 3,556

  14. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  15. EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

    Authors: Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist - Journal of Clinical Oncology 2018 cited by 471

  16. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer

    Authors: Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo‐Jack, Shirish M. Gadgeel, Katherine R. Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba R. Digumarthy, Colleen L. Channick, Colleen Keyes, Gad Getz, Dora Dias‐Santagata, Rebecca S. Heist, Jochen K. Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw - Cancer Discovery 2016 cited by 1,144

  17. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

    Authors: Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne - Cancer Discovery 2022 cited by 154

  18. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  19. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

    Authors: James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Mok, Martin Schüler, Nobuyuki Yamamoto, Chong‐Jen Yu, Sai‐Hong Ignatius Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi‐Long Wu - The Lancet Oncology 2015 cited by 982

  20. Therapy-induced APOBEC3A drives evolution of persistent cancer cells

    Authors: Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M. Siddiqui, Nicole Phan, Pégah Jalili, Daria Timonina, Samantha Bilton, María Gomez‐Caraballo, Hannah L. Archibald, Varuna Nangia, Kristin Dionne, Amanda K. Riley, Matthew A. Lawlor, Mandeep K. Banwait, Rosemary Cobb, Lee Zou, Nicholas J. Dyson, Christopher J. Ott, Cyril H. Benes, Gad Getz, Chang S. Chan, Alice T. Shaw, Justin F. Gainor, Jessica J. Lin, Lecia V. Sequist, Zofia Piotrowska, Beow Y. Yeap, Jeffrey A. Engelman, Jake June-Koo Lee, Yosef E. Maruvka, Rémi Buisson, Michael S. Lawrence, Aaron N. Hata - Nature 2023 cited by 145

  21. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

    Authors: Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman - Clinical Cancer Research 2015 cited by 548

  22. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

    Authors: Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Lone H. Ottesen, Paul Frewer, Xiaoling Ou, Geoffrey R. Oxnard - The Lancet Oncology 2020 cited by 413

  23. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

    Authors: Scott Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David C. Smith, Philip D. Leming, William J. Geese, Dennis J. Yoon, Ang Li, Julie R. Brahmer - Journal of Clinical Oncology 2018 cited by 749

  24. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    Authors: James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist - The Lancet Oncology 2015 cited by 1,580